Clinical trials / Connecticut
Psychedelic and ketamine trials recruiting in Connecticut
14 trials registered on ClinicalTrials.gov were recruiting at one or more sites in Connecticut on 26 Oct 2026. By substance: Ketamine / esketamine 5, Psilocybin 5, MDMA 2, DMT / ayahuasca 2. By condition: depression 8, ptsd 4, alcohol use disorder 2, opioid use disorder 1, anxiety 1, ocd 1, bipolar disorder 1.
From the ClinicalTrials.gov registry (US National Library of Medicine), read through its public API on 26 Oct 2026: studies marked as recruiting whose interventions name the substance. Titles, sponsors, phases, conditions and sites are the registry's own entries, written by the sponsors. We have not vetted any trial, and recruiting status changes; the registry record and the study team have the current eligibility rules.
Phase 3Ketamine / esketamineNCT06713616
PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study
- Conditions:
- Depression
- Sponsor:
- Yale University
- Who:
- ages 18 Years and over, 400 participants planned
- Mood Institute, Milford, Connecticut
- Yale School of Medicine, New Haven, Connecticut
ObservationalKetamine / esketamineNCT06725277
The OBSERVE Protocol
- Conditions:
- Major Depression Disorder
- Sponsor:
- Yale University
- Who:
- 450 participants planned
- Mood Institute, Milford, Connecticut
- Yale School of Medicine, New Haven, Connecticut
Early phase 1PsilocybinNCT07118332
Psilocybin as a Treatment for Chronic Pain in Smokers
- Conditions:
- Smokers With Chronic Pain
- Sponsor:
- Yale University
- Who:
- ages 21 Years to 65 Years, 10 participants planned
- Department of Veterans Affairs, West Haven, Connecticut (not yet recruiting)
- Department of Veterans Affairs, West Haven, Connecticut
Phase 2/3MDMANCT07118839
MDMA-Assisted Therapy for Veterans With PTSD and Alcohol Use Disorder (MAP VETS)
- Conditions:
- Post Traumatic Stress Disorder; Alcohol Use Disorder
- Sponsor:
- VA Office of Research and Development
- Who:
- ages 18 Years and over, 80 participants planned
- VA Connecticut Healthcare System West Haven Campus, West Haven, CT, West Haven, Connecticut
Phase 2Ketamine / esketamineNCT05786066
The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects
- Conditions:
- Depressive Disorder; Major Depressive Disorder; Bipolar Disorder; Post Traumatic Stress Disorder; Suicidal Ideation
- Sponsor:
- Yale University
- Who:
- ages 21 Years to 65 Years, 30 participants planned
- VA Connecticut Healthcare System, West Haven, Connecticut
Phase 1Ketamine / esketamineNCT05915013
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response
- Conditions:
- Depressive Disorder, Major; Post Traumatic Stress Disorder
- Sponsor:
- Yale University
- Who:
- ages 18 Years to 60 Years, 50 participants planned
- Yale University, New Haven, Connecticut
Phase 1DMT / ayahuascaNCT06070649
The Potential Therapeutic Effects of Psychedelic, N, N-dimethyltryptamine (DMT), on Alcohol Use Disorder (AUD)
- Conditions:
- Alcohol Use Disorder (AUD); Alcohol-Related Disorders; Alcohol Use
- Sponsor:
- Yale University
- Who:
- ages 21 Years to 65 Years, 63 participants planned
- Connecticut Mental Health Center, New Haven, Connecticut
Phase 1PsilocybinNCT06160284
Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD)
- Conditions:
- Opioid Use Disorder
- Sponsor:
- Yale University
- Who:
- ages 25 Years to 55 Years, 12 participants planned
- Yale University, New Haven, Connecticut
Phase 2Ketamine / esketamineNCT06402955
Imaging Depression in Parkinson's Disease
- Conditions:
- Parkinson's Disease; Major Depressive Disorder
- Sponsor:
- Yale University
- Who:
- ages 40 Years to 80 Years, 120 participants planned, accepts healthy volunteers
- Yale University, New Haven, Connecticut
Phase 1PsilocybinNCT06442423
Open-Label Psilocybin Study in Transdiagnostic Population
- Conditions:
- Transdiagnostic; Depression - Major Depressive Disorder; Anxiety; PTSD Symptoms; PTSD; Substance Use; Substance Use Disorder (SUD); OCD
- Sponsor:
- Yale University
- Who:
- ages 18 Years and over, 50 participants planned, accepts healthy volunteers
- Connecticut Mental Health Center - Yale School of Medicine, New Haven, Connecticut
Early phase 1PsilocybinNCT06464367
Mechanistic Studies of Psilocybin in Headache Disorders
- Conditions:
- Migraine
- Sponsor:
- Yale University
- Who:
- ages 21 Years to 70 Years, 50 participants planned, accepts healthy volunteers
- VA Connecticut Healthcare System, West Haven, Connecticut
Phase 1DMT / ayahuascaNCT06671977
Study of the Safety, Tolerability, Electrophysiological Effects and Efficacy of DMT in Humans (DMT-Bolus)
- Conditions:
- Major Depression Disorder; Depression
- Sponsor:
- Deepak C. D'Souza
- Who:
- ages 21 Years to 65 Years, 60 participants planned, accepts healthy volunteers
- Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine,, West Haven, Connecticut
Phase 2MDMANCT06683014
MDMA in Borderline Personality Disorder (MDMA in BPD)
- Conditions:
- Borderline Personality Disorder
- Sponsor:
- Yale University
- Who:
- ages 18 Years to 60 Years, 10 participants planned
- Connecticut Mental Health Center, New Haven, Connecticut
Phase 2PsilocybinNCT07610369
The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease (PSI-PD)
- Conditions:
- Depression; Parkinson's Disease (PD)
- Sponsor:
- Yale University
- Who:
- ages 40 Years to 80 Years, 40 participants planned
- Yale University, New Haven, Connecticut